Esophageal Adenocarcinoma Methods and Protocols

103

tive neoadjuvant therapy. There are some features adopted

in post-neoadjuvant therapy (Yp TNM) grouping that are

not in those without neoadjuvant therapy (pTNM)

grouping.

(B1) For post-neoadjuvant therapy (Yp) TNM group, cancer

grade does not affect the stage of the cancer.

(B2) Stage I and stage II do not have prognostic staging sub-

groups (in contrast to having stage IA, stage 1B, stage IC,

stage IIA, and stage IIB in pTNM grouping).

(B3) The criteria for grouping into prognostic stage group I,

stage II, stage III, and stage IVA are different.

References

1. Denoix PF (1946) Enquete permanent dans les
   centres anticancereaux. Bull Inst Nat Hyg
   1:70–75


2. UICC (1968) TNM pocket book, “the Livre
   de Poche”, 1st edn


3. American Joint Committee for Cancer Staging
   and end results reporting (1977) Manual for
   staging of cancer. American Joint Committee
   for Cancer Staging, Chicago, IL


4. UICC (1987) TNM classification, 4th edn


5. Beahrs OH, Henson DE, Hutter RVP, Myers
   MH (eds) (1988) Manual for staging of cancer,
   3rd edn. Lippincott, Philadelphia, PA


6. Edge SB, Byrd DR, Compton CC, Fritz AG,
   Greene FL, Trotti A (eds) (2010) Esophagus
   and esophagogastric junction. In: AJCC cancer
   staging manual, 7th edn, Part 3. Springer,
   New York, pp 103–155, Chapter 10


7. Rice TW, Kelsen D, Blackstone E, Ishwaran
   H, Patil DT, Bass AJ, Erasmus JJ, Gerdes H,
   Hofstetter WL (2016) Esophagus and esoph-
   agogastric junction. In: Amin MB, Edge S,
   Greene F, Byrd DR, Brookland RK,
   Washington MK, Gershenwald JE, Compton
   CC, Hess KR, Sullivan DC, Jessup JM,
   Brierley JD, Gaspar LE, Schilsky RL, Balch
   CM, Winchester DP, Asare EA, Madera M,
   Gress DM, Meyer LR (eds) AJCC cancer stag-
   ing manual, 8th edn. Springer, New York,
   pp 185–202. Chapter 16


8. Rice TW, Rusch VW, Apperson-Hansen C,
   Allen MS, Chen LQ, Hunter JG, Kesler KA,
   Law S, Lerut TE, Reed CE, Salo JA, Scott WJ,

Swisher SG, Watson TJ, Blackstone EH (2009)

Worldwide esophageal cancer collaboration.

Dis Esophagus 22:1–8

9. Lam AK (2015) Cellular and molecular biology
   of esophageal cancer. In: Saba NF, El-Rayes BF
   (eds) Esophageal cancer: prevention, diagnosis
   and therapy. Springer, New York, pp 25–40.
   Chapter 2, ISBN: 978-3-319-20068-2


10. Rizk NP, Ishwaran H, Rice TW, Chen LQ,
    Schipper PH, Kesler KA, Law S, Lerut TE,
    Reed CE, Salo JA, Scott WJ, Hofstetter WL,
    Watson TJ, Allen MS, Rusch VW, Blackstone
    EH (2010) Optimum lymphadenectomy for
    esophageal cancer. Ann Surg 251:46–50


11. Chen YJ, Schultheiss TE, Wong JY, Kernstine
    KH (2009) Impact of the number of resected
    and involved lymph nodes on esophageal can-
    cer survival. J Surg Oncol 100:127–132


12. Peyre CG, Hagen JA, DeMeester SR, Altorki
    NK, Ancona E, Griffin SM, Hölscher A, Lerut
    T, Law S, Rice TW, Ruol A, van Lanschot JJ,
    Wong J, DeMeester TR (2008) The number of
    lymph nodes removed predicts survival in
    esophageal cancer: an international study on
    the impact of extent of surgical resection. Ann
    Surg 248:549–556


13. Rice TW, Ishwaran H, Hofstetter WL, Schipper
    PH, Kesler KA, Law S, Lerut EM, Denlinger
    CE, Salo JA, Scott WJ, Watson TJ, Allen MS,
    Chen LQ, Rusch VW, Cerfolio RJ, Luketich JD,
    Duranceau A, Darling GE, Pera M, Apperson-
    Hansen C, Blackstone EH (2017) Esophageal
    cancer: associations with (pN+) lymph node
    metastases. Ann Surg 265:122–129

Pathological Staging and Esophageal Adenocarcinoma